Gilead Reports Q4 and Full Year 2025 Results: Record Growth in HIV and Liver Disease Drugs Gilead Sciences announces Q4 and full-year 2025 results, showcasing significant growth driven by new product launches and ongoing demand for HIV therapies.

Gilead Reports Q4 and Full Year 2025 Results: Record Growth in HIV and Liver Disease Drugs #United_States #Foster_City #Gilead_Sciences #Veklury #HIV

Gilead Sciences Reports Strong Q3 2025 Earnings with Product Sales Growth Gilead Sciences has reported its Q3 2025 earnings, showcasing a 4% increase in product sales excluding Veklury, highlighting a robust pipeline with anticipated growth.

Gilead Sciences Reports Strong Q3 2025 Earnings with Product Sales Growth #United_States #Foster_City #Trodelvy #Gilead_Sciences #Veklury

Gilead Sciences Reports Strong Q1 2025 Performance Igniting Future Growth Prospects Gilead Sciences posts robust Q1 2025 results, showcasing sales growth across key products and positive trial outcomes that signal bright prospects ahead.

Gilead Sciences Reports Strong Q1 2025 Performance Igniting Future Growth Prospects #USA #Foster_City #Trodelvy #Gilead_Sciences #Veklury